The global pharmaceutical company, Pfizer Inc. in association with BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to provide 300 million doses of a vaccine for COVID-19 in 2021
- As per signed agreement U.S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses
- Pfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial, and manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021
In July 2020, Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
In July 2020, Pfizer Inc. had pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.
In Dec 2019, Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies had been entered into a global license agreement for Theravance Biopharmas preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
Pfizer, headquartered in New York, United States, is a global pharmaceutical corporation. The company involves in discovery, development and manufacturing of health care products globally. Its global portfolio includes medicines and vaccines as well as many of the world’s best?known consumer health care products.